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Abstract
Process analytical technology (PAT)-tools were used to monitor freeze-drying of Bacille
Calmette-Guérin (BCG) at pilot and production scale. Among the evaluated PAT-tools,
there is the novel use of the vacuum valve open/close frequency for determining the end-
point of primary drying at production scale. The duration of primary drying, the BCG survival
rate, and the residual moisture content (RMC) were evaluated using two different freeze-
drying protocols and were found to be independent of the freeze-dryer scale evidencing
functional equivalence. The absence of an effect of the freeze-dryer scale on the process
underlines the feasibility of the pilot scale freeze-dryer for further BCG freeze-drying pro-
cess optimization which may be carried out using a medium without BCG.
Introduction
Lyophilization or freeze-drying is often used for stabilization of biopharmaceuticals such as
vaccines [1, 2]. Besides improvement of the stability of vaccines, lyophilization is used to facili-
tate the production of new dosage forms of vaccines [3, 4], such as bioneedles for intramuscular
delivery [5–8] or powders for pulmonary delivery [9, 10]. If properly formulated, lyophilized
vaccines are less prone to chemical and physical degradation pathways owing to the removal of
water and vaccine antigen vitrification in the formulation [11].
Bacille Calmette-Guérin (BCG) vaccine contains a non-infectious strain ofMycobacterium
bovis and is used prophylactic against tuberculosis or for immune therapy against bladder can-
cer [1, 12–14].
The process of freeze-drying includes besides a freezing step also two drying steps: primary
drying, and secondary drying. During primary drying ice is removed by sublimation and dur-
ing secondary drying water is removed by desorption [2, 11, 15].
The strategy for the design of a freeze-drying process is generally based on the physical
properties of the formulation in order to aim at a freeze-dried product with an intact cake
structure. The occurrence of cake collapse, although not necessarily detrimental for the
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product, is often unwanted and may pose a reason for rejection of that vial. Collapse may occur
during lyophilization by raising the product temperature (Tp) above a critical threshold, the
onset collapse temperature (Toc). The Toc depends on the composition of the formulation and
may be determined by freeze-drying microscopy (FDM) [15]. For amorphous solids, collapse
may occur upon raising the product temperature to or slightly beyond the glass transition tem-
perature of the maximally freeze-concentrated fraction (Tg
0
). In the case of crystalline excipi-
ents, collapse may occur upon increasing the Tp to the eutectic temperature (Te). Both
amorphous and crystalline components may be present in a single formulation [2].
Collapse can be prevented by choosing an appropriate shelf temperature and chamber pres-
sure to ensure the Tp to remain below the Toc during primary drying [2, 15]. Optimal process
conditions for primary drying may be characterized by a minimum duration of primary drying
and a maintained cake structure. This is relevant since freeze-drying is a lengthy process [2]
especially in the case of non-optimized lyophilization cycles. In general, optimization of the
duration of primary drying gives the biggest efficiency gain in lyophilization, resulting in less
process time, and increased production capacity.
The aim of this study is to demonstrate product (RMC and BCG survival rate) and process
(read: primary drying time) equivalence of pilot scale (total shelf area 2.7 m2) and production
scale (total shelf area 43.2 m2) freeze-drying of BCG to support further BCG freeze-drying pro-
cess optimization at pilot scale. This will be done by using both well-known PAT-tools, the
pressure rise test (PRT) [16], Tp [17], a balance [18], and the condenser temperature [19], and
a, to our knowledge, novel PAT-tool, which is the open/close frequency of the vacuum valve
used for chamber pressure control. This frequency is indirectly determined from the saw-tooth
pattern in the recorded graphs of the registered chamber pressure during freeze-drying. Process
equivalence may also be demonstrated by showing that Tp-profiles (Tp vs time) are indepen-
dent of the freeze-dryer scale [20–23], however, GMP-restrictions, did not allow measurement
of the Tp at production scale. For that reason, alternative in-process parameters were consid-
ered as (scale-dependent) PAT-tools to monitor primary drying and determine the endpoint
thereof.
The comparison of freeze-drying processes as a function of dryer scale has been docu-
mented before [24, 25]. This study contributes to the existing knowledge by providing a sub-
stantial experimental data set on two freeze-drying cycles, which gives insight in process
variation and equipment related factors (if present).
Materials and Methods
Description of formulation, products and materials
After cultivation, BCG was pelleted by centrifugation and formulated in freeze-drying medium
[14, 26]. One liter of freeze-drying medium (HGT-medium) contains 108 g glucose, 25 g poly-
geline (Thera Select unless stated otherwise.) and 0.05 g Tween80.
Prior to freeze-drying 23 mL vials are filled with either MiliQ (purified water), HGT-
medium, or formulated BCG to reach a total volume of 10 mL/vial (fill height = 2.0 cm) which
are equipped with stoppers (Helvoet Pharma, The Netherlands).
Freeze-drying was performed at pilot scale (Klee, shelf surface area: 2.7 m2) and/or produc-
tion scale (Klee, shelf surface area: 43.2 m2). The pilot freeze-dryer contains 5 shelves, including
a sampling shelf and balance shelf. The sampling shelf is suitable to be completely transported
to the interior of a transparent Perspex chamber mounted on the freeze-dryer door from where
vials can be closed and/or removed during the freeze-drying process using a sample thief.
Comparison of Pilot and Production Scale Freeze-Drying
PLOS ONE | DOI:10.1371/journal.pone.0151239 March 16, 2016 2 / 13
temperature; Tg0 , Glass transition temperature of the
maximally freeze-concentrated fraction; PRT,
Pressure rise test.
Freeze-drying protocols
Freeze-drying was performed according to two cycles, I and II (see Table 1).
In these cycles, a PRT was performed as indicated. If the PRT-criterion (pressure rise< 0.03
mbar/min) of cycle II was not met, an extra drying time of 2 hours was added after which
another PRT was performed ultimately till the end of primary drying was reached (the PRT-
criterion was met) after which secondary drying was started.
The difference in chamber pressure during secondary drying between cycle I and II was pre-
sumed not to impact product quality since the water desorption rate in the cycles used is inde-
pended of the chamber pressure below 0.27 mbar [2].
Demonstrating equivalent drying behavior of HGT-medium and BCG in
HGT-medium
Drying of HGT-medium and BCG in HGT-medium was investigated using a fully loaded pilot
freeze-dryer. The freeze-dryer predominantly contained BCG in HGT-medium. On the sam-
pling shelf, HGT-medium and BCG in HGT-medium were placed next to each other (in sets of
three each). A sample thief was used to stopper and remove vials during freeze-drying accord-
ing to cycle II.
Effect of chamber pressure on the sublimation rate
A series of independent experiments was performed in the pilot freeze-dryer to study the effect
of the chamber pressure (from 0.01 to 0.5 mbar) on the sublimation rate. Vials were filled with
either 10 mL MiliQ or HGT-medium, stoppered, and loaded onto the balance shelf (~ 79 vials)
and the sampling shelf (~ 79 vials). In order to reduce the impact of external heat radiation, the
Perspex chamber was covered with aluminum foil. Freezing was performed as described before
(see Table 1). During primary drying at the studied chamber pressure, the shelves were held 1
hour at -35°C, then in 0.5 hour to -30°C and thereafter, up to 40 hours at -30°C. The average
sublimation rate to remove 100 g of ice was calculated from the decrease in mass over time.
Table 1. Freeze-drying protocols as used in this study (PD = primary drying, and SD = secondary drying). The pressure rise test (PRT) in cycle I was
used to confirm the end of primary drying. In cycle II the PRT was used during primary drying and after not meeting the criterion (maximum rise in pressure
<0.03 mbar/min) the primary drying stage was prolonged by an additional 2 hours.
Cycle I Cycle II
Step t (hours) T (°C) p (mbar) t (hours) T (°C) p (mbar)
Loading +4 ~1000 +4 ~1000
Equilibration 3 to -15 ~1000 3 to -15 ~1000
1 -15 ~1000 1 -15 ~1000
Freezing 1 to -35 ~1000 1 to -35 ~1000
1 -35 ~1000 1 -35 ~1000
PD 1 -35 0.045 1 -35 0.09
0.5 to -30 0.045 0.5 to -30 0.09
227, PRT -30 0.045 90 -30 0.09
2, PRT -30 0.09
SD 30 +30 0.045 30 +30 0.09
30 +30 0.007 30 +30 0.046
doi:10.1371/journal.pone.0151239.t001
Comparison of Pilot and Production Scale Freeze-Drying
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Analytical testing
BCG survival. For determination of the BCG survival, a dilution series was prepared in
Sauton solution (freeze-dried material was resuspended in physiological salt solution) and the
number of viable BCG bacteria, before and after freeze-drying, were determined by counting
the colonies grown (at a temperature of 36 ± 0.5°C for at least 28 days) on Loewenstein agar
plates.
Results are reported as the average BCG survival of three randomly selected vials (this repre-
sents an analysis result).
Residual moisture content. The residual moisture content (RMC) was determined using
a Karl Fischer coulometric titrimeter (Model CA-06 moisture meter, Mitsubishi). The samples
were weighed, subsequently reconstituted in 10 mL Coulomat A (Fluka, Switzerland) and a vol-
ume of 0.1 mL was injected into the titration vessel. The mass of the dried material was calcu-
lated by also determining the mass of the empty vial (+stopper). The RMC was calculated
based on the measured water content, the mass of the dried material, the reconstitution vol-
ume, the injection volume and the water content of the blank.
To obtain an analysis result, the average RMC of three vials (randomly selected from the
batch) was calculated.
Statistical analysis
The statistical analysis were performed using Student’s t-test with P< 0.05 as the minimal
level of significance.
The number of experiments (n) refers to the number of analysis results, or primary drying
times from independent experiments.
Average values are presented ± standard deviation.
Results
Scale-dependent PAT-tools for monitoring primary drying
Several in-process parameters, PAT-tools, are available for monitoring BCG primary drying at
pilot and production scale (see Table 2) of which the PRT is available in both freeze-dryers.
At production scale, the PRT is only routinely used to confirm the endpoint after the fixed
primary drying time of 228.5 hours. By using the PRT for process monitoring (see Fig 1) it can
be seen that this fixed period of time is longer than strictly required, i.e. the required time for
primary drying is 150–160 hours as by then the pressure rise is very low and almost constant.
Table 2. Overview of in-process parameters at pilot and production scale that are useful for monitor-
ing primary drying and primary drying endpoint determination.
Feasibility for primary drying endpoint
determination
Parameter Production scale Pilot scale
Pressure rise test + +
Product temperature (Tp) - +
Mass (balance shelf) - +
Outlet condenser temperature + -
Vacuum valve* + -
* Refers to changes in the chamber pressure caused by opening and closing of the vacuum valve.
doi:10.1371/journal.pone.0151239.t002
Comparison of Pilot and Production Scale Freeze-Drying
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The observed trend in values from the PRT corresponds to time profiles of the outlet con-
denser temperature (see Fig 1A) and the vacuum valve open/close frequency (see Fig 1B)
evidencing the use of these methods for monitoring the primary drying process.
In the pilot freeze-dryer, use of the balance shelf and external thermocouples were evaluated
for determination of the endpoint of primary drying (data not shown). It appeared that passing
the PRT criterion also coincided with: A) no further decrease in mass of vials placed on the bal-
ance shelf and B) a constant apparent product temperature that is generally above the shelf
temperature.
Functional equivalence of BCG freeze-drying
Freeze-drying according to cycle I. Production scale freeze-drying of BCG is done
according to a non-optimized freeze-drying cycle (cycle I) which consistently yields product
(see Table 3) with a BCG survival rate of 7.4 ± 2.5% (n = 14), and an RMC of 0.78 ± 0.08%
(n = 14).
Estimating the duration of primary drying using the vacuum-valve-method and the outlet-
condenser-temperature-method indicated that a duration of ~162 hours (instead of 228.5 hours)
appeared already sufficient to remove all ice. Pilot scale freeze-drying resulted in an average pri-
mary drying time of ~153 hours, which was not significantly different from the production scale
value (p> 0.05).
Fig 1. Measured in-process parameters during freeze-drying of BCG at production scale. Panel A shows the outlet condenser temperature (clear
triangle). Panel B shows the open/close frequency of the valve connecting the chamber and the vacuum pump (clear square). In both panels the rise in
pressure in one minute from the PRT is shown (black circle).
doi:10.1371/journal.pone.0151239.g001
Table 3. Overview of primary time (hours), RMC (%), and BCG survival rate (%) as a function of the freeze-drying cycle and freeze-dryer scale. Sev-
eral methods were used for primary drying endpoint determination: the vacuum valve open/close frequency, the outlet condenser temperature, and PRT
refers to the pressure rise test. The maximum load of the freeze-dryers is as follows: 12500 vials at production scale and 750 vials at pilot scale. See S1 Data
for raw data.
Final product
Description Vials PD time (hours) RMC (%) Survival (%)
Cycle I
Production scale
Fixed time ~ 10500 228.5 0.78 ± 0.08 (n = 14) 7.4 ± 2.5 (n = 14)
Vacuum valve 164.2 ± 3.1 (n = 6)
Outlet cond. temp. 158.3 ± 5.7 (n = 6)
Overall 161.3 ± 6.5
Pilot scale
• PRT ~ 750 153.5 (n = 2) 0.82 (n = 2) -
~ 160 150.7 (n = 1) - -
Overall 152.5 ± 5.5
Cycle II*
Production scale
• PRT ~ 10500 129.0 ± 2 (n = 3) 0.83 ± 0.06 (n = 3) 8.4 ± 2.5 (n = 3)
Pilot scale
• PRT ~ 750 120.6 ± 6 (n = 4) 0.80 ± 0.07 (n = 3) 7.7 ± 3.0 (n = 3)
~ 160 131.3 (n = 1) - -
Overall 122.9 ± 7.0
* The supplier of the polygeline component was Piramal.
doi:10.1371/journal.pone.0151239.t003
Comparison of Pilot and Production Scale Freeze-Drying
PLOS ONE | DOI:10.1371/journal.pone.0151239 March 16, 2016 6 / 13
Selecting a more favorable chamber pressure. In order to study the effect of a process
change as function of freeze-dryer scale, a more favorable chamber pressure was selected by
confirming the well-known effect of the chamber pressure on the sublimation rate [25, 27]. Fig
2 shows that a higher sublimation rate may be obtained by applying a chamber pressure of 0.09
mbar (in cycle II) instead of 0.045 mbar (as used in cycle I) to freeze-dry both purified water
and HGT-medium. In all cases, the HGT cake structure was maintained during the course of
the experiment.
Freeze-drying according to cycle II. At production scale, a primary drying time of ~129
hours was obtained, a gain in process time of ~30 hours compared to cycle I (see Table 3). The
BCG survival rate was 8.4 ± 2.5% and the RMC 0.83 ± 0.06%. The primary drying time, BCG
survival rate, and RMC did not differ significantly (p> 0.05) from those observed at pilot
scale. The results from cycle I and II were used to demonstrate functional equivalence of pilot
and production scale freeze-drying of BCG.
The feasibility of the pilot scale freeze-dryer as a down-scale model for further freeze-drying
cycle optimization was confirmed further by freeze-drying an experimental HGT-medium
(without BCG).
Fig 2. Effect of the chamber pressure on the average sublimation rate of HGT-medium (black circle), and purified water (clear circle) in the pilot
freeze-dryer. The sublimation rate was calculated from the time course to sublimate 100 g of ice.
doi:10.1371/journal.pone.0151239.g002
Comparison of Pilot and Production Scale Freeze-Drying
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The available and relevant in-process parameters showed an evident change after ~116
hours of primary drying (see the vertical line in Fig 3A–3C).
This change likely illustrated a decrease in the overall sublimation rate, as concluded from
the slower loss in mass of vials on the balance shelf in the pilot scale freeze-dryer beyond ~116
hours of primary drying (see Fig 3C). This time course may be explained by a decreasing num-
ber of vials still containing ice, i.e. the drying rate of edge vials is known to be higher than that
of centre vials [24, 28–30]. Therefore, the vertical line in Fig 3A–3C apparently marks the
moment at which vials at (and/or close to) the edge no longer contain ice. This suggests that
primary drying of edge vials was independent of the dryer scale.
At production scale, the inlet condenser temperature (see Fig 3A) showed a constant mini-
mum of ~-80°C. Apparently, there is a substantial amount of heat transferred to the condenser
during solidification of water vapour onto the condenser, which is reflected by a higher initial
outlet condenser temperature of ~-60°C. A lower overall sublimation rate (beyond ~116 hours)
results in a lower outlet condenser temperature because less heat is transferred to the con-
denser. This means that the observed pattern in condenser outlet temperature is related to the
cooling capacity of the equipment.
The observed pattern in the vacuum valve open/close frequency of the production scale
freeze-dryer (see Fig 3B) may be explained by the decreasing need to adjust the chamber pres-
sure near the end of primary drying.
The increase in pressure from the PRT was included as a control (see Fig 3A and 3B) and
was found to parallel the outlet condenser temperature and the vacuum valve open/close fre-
quency. This confirmed the suitability of both methods for primary drying endpoint determi-
nation as described earlier.
In the pilot scale freeze-dryer, the apparent product temperature of a centre vial on the sam-
pling shelf is clearly below the shelf temperature of -30°C during sublimation (see Fig 3C). The
product temperature increases as cooling of the vial decreases, beyond a primary drying time
of ~116 hours. At the end of primary drying, the product reaches a temperature above the shelf
temperature due to outside heat radiation.
In an independent experiment, it was tested whether freeze-drying of HGT-medium would be
representative for BCG freeze-drying. Fig 4 shows that the removal of moisture, reflected by a
decrease in vial content and RMC, is comparable. This shows that further cycle improvement may
be performed with HGT-medium (or mostly HGT-medium and some vials containing BCG).
Discussion
PAT-tools for monitoring primary drying and demonstrating process
equivalence
This study introduces a novel PAT tool, the vacuum valve open/close frequency for monitoring
primary drying and determination of the primary drying endpoint. Opening and closing of the
Fig 3. A comparison of in-process data upon using the shortened freeze-drying process during primary
drying (PD) of HGT-medium (supplier of the polygeline was BBraun) at production scale (panel A and B) and
pilot scale (panel C) in the time-frame from 90 hours till the end. Panel A shows the outlet (clear triangle) and
inlet condenser temperature (black triangle), and the pressure rise obtained after 1 minute performing the
PRT (black circle). Panel B shows the open/close frequency of the valve between the vacuum pump and the
chamber (clear square). The pressure rise from the PRT is included as well for comparison (black circle).
Panel C shows the decrease in mass (black diamond) and the temperature of a vial that is placed in the
centre of the array and thereby shielded from outside heat radiation (clear diamond). The straight grey line in
panel C serves as a visual aid to show a reduced decrease in mass beyond ~116 hours. The vertical line in
panel A-C marks a primary drying time of ~116 hours after which marked changes in the studied in-process
parameters are noted.
doi:10.1371/journal.pone.0151239.g003
Comparison of Pilot and Production Scale Freeze-Drying
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vacuum valve resulted in a typical saw-tooth pattern in the chamber pressure (not shown)
which was registered during BCG freeze-drying. The fact that the production scale process is
apparently not operated at a constant chamber pressure is not ideal and for that reason, most
production scale freeze-dryers are currently equipped with a calibrated leak. In such a case, it is
possible to use the bleed rate of (sterile) N2 into the freeze-dryer as a PAT-tool for process
monitoring [19].
Besides these two tools, there are many more available in the literature [16] of which use of
the PRT [16], Tp [17], balance [18], and condenser temperature [19] as used in this study are
well-known examples.
Demonstrating process equivalence is preferred in case of process transfer to another
freeze-dryer. In such a case, the product temperature vs time profiles should ideally be the
same [20–23]. With respect to the duration of primary drying, the Tp of centered vials is rele-
vant as these are generally colder than edge vials and will need more time to dry. Edge vials
Fig 4. Freeze-drying of 10 mL HGT-medium and BCG in HGT-medium in the pilot freeze-dryer. Depicted are: the vial content (g) of BCG in HGT-
medium (black circle) and HGT-medium (clear circle) and the RMC (%) of BCG in HGT-medium (black square) and HGT-medium (clear square). Each dot
represents an average value ± standard deviation (n = 3). The solid horizontal line shows represent the total process time. The stars mark the beginning of
primary, and secondary drying.
doi:10.1371/journal.pone.0151239.g004
Comparison of Pilot and Production Scale Freeze-Drying
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may be relevant for studying the visual appearance of the cake. In this study, the visual appear-
ance (mostly intact with only small dents at the bottom) of the cake was independent of the
dryer scale and position of the vial indicating that in all cases the Tp was below the critical
threshold and therefore visible cake collapse did not occur.
This study shows that besides measurement of Tp also other in-process parameters appear
useful to demonstrate process equivalence upon operating different freeze-dryers as also
explained elsewhere [19].
Effect of freeze-dryer scale and other factors on primary drying
There are several examples described in the literature on the comparison of processes operated in
different freeze-dryers [24, 25, 31]. Running the same cycle in different freeze-dryers is no guar-
antee for process equivalence as several (scale dependent) factors may affect the process [19–21].
A GMP production scale freeze-drying environment may be cleaner (less particles) than a
research setting which in turn may result in a higher degree of supercooling during freezing at
production scale. Compared to pilot scale freezing, this may result in the formation of smaller
ice crystals, a higher average Tp, and a longer primary drying time approximating 1% of the
total PD time/°C of extra supercooling [17, 18]. In this study, no difference in primary drying
time was noted. Probably, the equilibration step, in which the vials are kept at -15°C for 1 hour
before freezing, and/or the presence of sufficient (bacterial) nucleation sites [32] minimize(s)
freezing differences.
Also the dryer load may affect the primary drying time [22]. In this study, this possibility
was addressed by lowering the number of vials in the pilot scale freeze-dryer. It was found that
a lower load of 20% (a fully loaded middle shelf, i.e. loaded with two cassettes) did not result in
a reduced primary drying time (see Table 3) likely because the percentage of warm edge vials
remained unchanged.
Interestingly, the observed variation in the determined primary drying time (see Table 3) is
relatively small (RSD< 6%). This experimental base is in support of a theoretical approach,
which allows calculation of for example the effect of shelf temperature on the primary drying
time. Typically, such calculations appear satisfactory [23], suggesting that inherent freeze-dry-
ing process variation is small in general.
Outlook towards process time reduction of BCG freeze-drying
It was demonstrated here that pilot scale freeze-drying resembled the production scale process
suggesting suitability of the pilot scale freeze-dryer for future process optimization. For optimi-
zation experiments, use of HGT-medium (for example supplemented with some BCG vials) is
possible as drying was not affected by the presence of BCG (see Fig 4).
It is conceivable that process time reduction may be obtained by increasing the shelf tem-
perature. A short study indicated that the use of a shelf temperature gradient during primary
drying could significantly reduce the primary drying time without affecting the cake appear-
ance (data not shown), but this cycle was not implemented at production scale.
Besides shortening the duration of primary drying it may also be possible to reduce the sec-
ondary drying time by for example increasing the shelf temperature ramp rate of the first sec-
ondary drying step (see Table 1) as explained elsewhere [2].
Risks related to process transfer from a pilot to a production scale
freeze-dryer
The freeze-drying cycles studied here use a constant shelf temperature for primary drying. It
was anticipated that this would mitigate risks involved in process transfer, i.e. avoid process
Comparison of Pilot and Production Scale Freeze-Drying
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differences associated to uneven heating of shelves, and/or temperature lag of which both are
conceivable in case of a (steep) shelf temperature gradient. The introduction of extra primary
drying time (10 h) after the estimated endpoint of primary drying would mitigate the risk for
the occurrence of melt back in vials located in the center of an array (not required in this
study).
The risk for the occurrence of evident cake collapse in edge vials was not anticipated (at
least in the case of BCG freeze-drying) because the impact of heat radiation is generally less in
a production scale freeze-dryer.
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